{"product_id":"retatrutide-ly3437943-peptide-intelligence-monograph","title":"Retatrutide (LY3437943) — Peptide Intelligence Monograph","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eRetatrutide (LY3437943): Evidence Before Hype\u003c\/strong\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eRetatrutide is an investigational peptide-based triple receptor agonist targeting the GIP, GLP-1, and glucagon receptors. Its clinical development has generated significant interest because of substantial effects reported in obesity and cardiometabolic research.\u003c\/p\u003e\n\u003cp\u003eThe Founder’s Institute of Medicine \u0026amp; Education Retatrutide Peptide Intelligence Monograph examines the scientific evidence behind that interest — separating published clinical findings and emerging Phase 3 evidence from claims that extend beyond what has been established.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInside the monograph:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Compound identity and triple-agonist pharmacology\u003cbr\u003e• GIP, GLP-1, and glucagon receptor mechanisms\u003cbr\u003e• Phase 2 obesity and metabolic evidence\u003cbr\u003e• Phase 3 TRIUMPH clinical evidence\u003cbr\u003e• Weight loss and body-composition findings\u003cbr\u003e• Type 2 diabetes and glycemic outcomes\u003cbr\u003e• Cardiometabolic research\u003cbr\u003e• OSA, osteoarthritis, and MASLD research\u003cbr\u003e• Safety, tolerability, and heart-rate considerations\u003cbr\u003e• Comparison with established incretin therapies\u003cbr\u003e• Investigational and regulatory status\u003cbr\u003e• Risks surrounding unauthorized “research peptide” products\u003cbr\u003e• Claim-by-claim FIPES evidence assessment\u003cbr\u003e• Fully referenced scientific literature\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstitute Bottom Line:\u003c\/strong\u003e Retatrutide has produced substantial clinical findings and represents an important emerging metabolic therapy, but it remains investigational. Clinical promise should not be confused with regulatory approval or established routine clinical use.\u003c\/p\u003e","brand":"Founder's Institute of Medicine \u0026 Education","offers":[{"title":"Default Title","offer_id":45383646314678,"sku":null,"price":24.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0736\/0990\/4310\/files\/ChatGPTImageAug25_2026_03_50_29PM.png?v=1787702231","url":"https:\/\/foundersinstitutemed.org\/products\/retatrutide-ly3437943-peptide-intelligence-monograph","provider":"Founder's Institute of Medicine \u0026 Education","version":"1.0","type":"link"}